comprehensive -WSS

comprehensive

author：comprehensive 2025-09-28 05:04:36 - browse：3122

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Goldman Sachs launches $650M fund for life science investments

knowledge

WSS

Chimpanzees, like humans and whales, get menopause: Study

Telehealth options flood the market as retailers push virtual care

Federal weight loss drug coverage is 30 years out of date

Telehealth options flood the market as retailers push virtual care

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Eli Lilly to pay $200M for Beam’s stake in gene

focus

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

Tori Bowie and the unacceptable rates of Black maternal death

Traditional Chinese medicine benefits explored in new JAMA study

In age of alternative facts, a scholarly course on calling out crap

Insitro, AI biotech unicorn, brings cash, new research to JPM 2024

How to save PrEP access — and even expand it

Antibiotic resistance and the global rise in human conflict

Moonlake's readout produced a cash windfall. Risks remain

The FDA weighs the risks of candy

Bright Health sells Medicare Advantage business to Molina

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

explore

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

The FDA must approve intranasal treatments for anaphylaxis

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

UCB departs biotech trade group BIO

At JPM, Bristol Myers Squibb CEO tries to soothe investor nerves

Readout Newsletter: What happened with Sarepta's Duchenne data

hotspot

leisure time

knowledge

explore